Cellectis S.A. SEC filings CLLS
Cellectis S.A. has 534 filings in SEC EDGAR's recent list, going back to Dec 19, 2014. Its latest annual report, Form 20-F, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 28, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 6, 2026 | — |
| S-8 | Employee stock plan registration | Sep 12, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Jul 2, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Jan 15, 2025 | — |
| S-8 | Employee stock plan registration | Jan 15, 2025 | — |
| S-8 | Employee stock plan registration | Aug 7, 2023 | — |
| 424B5 | Prospectus supplement | Feb 3, 2023 | — |
| 424B5 | Prospectus supplement | Feb 2, 2023 | — |
| FWP | Free writing prospectus | Jan 4, 2023 | — |
| 424B5 | Prospectus supplement | Jan 4, 2023 | — |
| S-8 | Employee stock plan registration | Oct 6, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | Jun 24, 2022 | — |
| S-8 POS | Filing | Mar 3, 2022 | — |
| S-8 | Employee stock plan registration | Aug 5, 2021 | — |
| 424B5 | Prospectus supplement | Mar 29, 2021 | — |
| S-8 POS | Filing | Mar 4, 2021 | — |
| 424B5 | Prospectus supplement | Dec 15, 2020 | — |
| FWP | Free writing prospectus | Dec 14, 2020 | — |
| F-3ASR | Filing | Jun 2, 2020 | — |
| 424B3 | Prospectus | Oct 15, 2018 | — |
| S-8 | Employee stock plan registration | Oct 5, 2018 | — |
| S-8 POS | Filing | Apr 13, 2018 | — |
| 424B5 | Prospectus supplement | Apr 6, 2018 | — |
| 424B5 | Prospectus supplement | Apr 4, 2018 | — |
| 424B5 | Prospectus supplement | Apr 3, 2018 | — |
| S-8 | Employee stock plan registration | Jan 9, 2018 | — |
| F-3 | Shelf registration (foreign issuer) | Mar 31, 2017 | — |
| S-8 | Employee stock plan registration | Dec 2, 2016 | — |
| F-3ASR | Filing | May 6, 2016 | — |
| S-8 | Employee stock plan registration | May 15, 2015 | — |
| 424B1 | Filing | Mar 26, 2015 | — |
| F-1MEF | F-1 mef | Mar 24, 2015 | — |
| FWP | Free writing prospectus | Mar 24, 2015 | — |
| F-1/A | Amendment no. 4 to form f-1 | Mar 24, 2015 | — |
| F-1/A | Amendment no. 3 to form f-1 | Mar 18, 2015 | — |
| F-1/A | Filing | Mar 12, 2015 | — |
| F-1/A | Form f-1/a (amendment no. 1) | Mar 10, 2015 | — |
| F-6 | Filing | Mar 4, 2015 | — |
| F-1 | Registration statement (foreign issuer) | Feb 20, 2015 | — |
Showing 39 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Paris, Lle-De-France
- SEC filer status
- Accelerated filer
- SEC CIK
- 1627281
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.